|
Radium-223 (Ra-223) versus novel antihormone therapy (NAH) for progressive metastatic castration-resistant prostate cancer (mCRPC) after 1 line of NAH: RADIANT, an international phase 4, randomized, open-label study. |
|
|
Honoraria - Astellas Pharma (Inst); Bayer; Janssen (Inst); Sanofi (Inst) |
Consulting or Advisory Role - Amgen (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Bayer; Bristol-Myers Squibb; Clovis Oncology; Curevac; ESSA (Inst); Janssen Oncology (Inst); Orion; Sanofi (Inst) |
Travel, Accommodations, Expenses - Janssen; MSD |
|
Aránzazu González del Alba |
No Relationships to Disclose |
|
|
Honoraria - Astellas Pharma; Janssen Oncology (Inst); Novartis |
Consulting or Advisory Role - AstraZeneca; MSD Oncology |
Speakers' Bureau - AstraZeneca |
Travel, Accommodations, Expenses - AstraZeneca |
|
|
Consulting or Advisory Role - Astellas Pharma; Bayer; Janssen Oncology |
Speakers' Bureau - Astellas Pharma; Bayer; Janssen Oncology |
Research Funding - Astellas Pharma (Inst); Bayer (Inst); Janssen Oncology (Inst) |
Travel, Accommodations, Expenses - Astellas Pharma; Bayer; Janssen Oncology |
|
|
|
Stock and Other Ownership Interests - Bayer |
|
|
No Relationships to Disclose |
|
|
|
Stock and Other Ownership Interests - Bayer |
|
|
|
Stock and Other Ownership Interests - Bayer |
|
|
Honoraria - Amgen; Astellas Pharma; AstraZeneca; Bayer/Vital; Bristol-Myers Squibb; Eisai; EUSA Pharma; Ipsen; Janssen-Cilag; Merck; MSD; Novartis; Pfizer; Roche; Sanofi/Aventis |
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Bayer; Bristol-Myers Squibb; Eisai; ipsen; Janssen-Cilag; Merck; MSD; Novartis; Roche; Sanofi |
Research Funding - Janssen-Cilag |
Travel, Accommodations, Expenses - Amgen; Bayer; Janssen-Cilag |